Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder characterized by slow-growing, fluid-filled cysts in both kidneys. Liver and pancreatic cysts as well as cardiac and vascular abnormalities variably occur [1,2]. ADPKD symptoms include hypertension, kidney pain, hematuria, cyst infection, and urinary tract infections [1]. Over time, deteriorating kidney function leads to end stage renal disease (ESRD). While most ADPKD patients progress to ESRD by age 70, many reach it at younger ages [3]. Despite recent advances in therapy, ADPKD remains incurable, and for most patients treatment is limited to symptom management [4]. For patients with ESRD, renal replacement therapy in the form of dialysis or transplant is inevitable. Unfortunately, renal transplantation does not cure ESRD and patients commonly experience acute rejection, cardiovascular diseases, infection, and malignancy [5].